AMPH - Amphastar Pharmaceuticals, Inc.
19.83
-1.180 -5.951%
Share volume: 740,581
Last Updated: 03-03-2026
Pharmaceutical Products/Pharmaceutical Preparations:
3.15%
PREVIOUS CLOSE
CHG
CHG%
$21.01
-1.18
-0.06%
Fundamental analysis
56%
Profitability
61%
Dept financing
32%
Liquidity
75%
Performance
53%
Performance
5 Days
-1.98%
1 Month
-30.69%
3 Months
-26.96%
6 Months
-32.07%
1 Year
-28.20%
2 Year
-57.52%
Key data
Stock price
$19.83
DAY RANGE
$19.81 - $21.07
52 WEEK RANGE
$19.81 - $31.26
52 WEEK CHANGE
-$29.33
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
08-06-2025
Company detail
CEO: Yong F. Zhang
Region: US
Website: amphastar.com
Employees: 1,620
IPO year: 2014
Issue type: Common Stock
Market: XNAS
Industry: Pharmaceutical Products/Pharmaceutical Preparations
Sector: Manufacturing
Region: US
Website: amphastar.com
Employees: 1,620
IPO year: 2014
Issue type: Common Stock
Market: XNAS
Industry: Pharmaceutical Products/Pharmaceutical Preparations
Sector: Manufacturing
Amphastar Pharmaceuticals, Inc., a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. It offers Primatene Mist, an over-the-counter epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma. The company also provides Amphadase, a bovine-sourced hyaluronidase injection to absorb and disperse other injected drugs.
Recent news